114 related articles for article (PubMed ID: 23123335)
1. Features and full reversibility of the renal toxicity of the ruthenium-based drug NAMI-A in mice.
Vadori M; Pacor S; Vita F; Zorzet S; Cocchietto M; Sava G
J Inorg Biochem; 2013 Jan; 118():21-7. PubMed ID: 23123335
[TBL] [Abstract][Full Text] [Related]
2. In vitro cell cycle arrest, in vivo action on solid metastasizing tumors, and host toxicity of the antimetastatic drug NAMI-A and cisplatin.
Bergamo A; Gagliardi R; Scarcia V; Furlani A; Alessio E; Mestroni G; Sava G
J Pharmacol Exp Ther; 1999 Apr; 289(1):559-64. PubMed ID: 10087050
[TBL] [Abstract][Full Text] [Related]
3. Tumour cell uptake G2-M accumulation and cytotoxicity of NAMI-A on TS/A adenocarcinoma cells.
Bergamo A; Zorzet S; Cocchietto M; Carotenuto ME; Magnarin M; Sava G
Anticancer Res; 2001; 21(3B):1893-8. PubMed ID: 11497274
[TBL] [Abstract][Full Text] [Related]
4. Fate of the antimetastatic ruthenium complex ImH [trans-RuCl4(DMSO)Im] after acute i.v. treatment in mice.
Cocchietto M; Salerno G; Alessio E; Mestroni G; Sava G
Anticancer Res; 2000; 20(1A):197-202. PubMed ID: 10769655
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Pluim D; van Waardenburg RC; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2004 Jul; 54(1):71-8. PubMed ID: 15034754
[TBL] [Abstract][Full Text] [Related]
6. Blood concentration and toxicity of the antimetastasis agent NAMI-A following repeated intravenous treatment in mice.
Cocchietto M; Sava G
Pharmacol Toxicol; 2000 Nov; 87(5):193-7. PubMed ID: 11129497
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of B16 melanoma metastases with the ruthenium complex imidazolium trans-imidazoledimethylsulfoxide-tetrachlororuthenate and down-regulation of tumor cell invasion.
Gava B; Zorzet S; Spessotto P; Cocchietto M; Sava G
J Pharmacol Exp Ther; 2006 Apr; 317(1):284-91. PubMed ID: 16368900
[TBL] [Abstract][Full Text] [Related]
8. Primary tumor, lung and kidney retention and antimetastasis effect of NAMI-A following different routes of administration.
Cocchietto M; Zorzet S; Sorc A; Sava G
Invest New Drugs; 2003 Feb; 21(1):55-62. PubMed ID: 12795530
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy of the antimetastatic compound NAMI-A and electroporation on B16F1 tumour cells in vitro.
Bicek A; Turel I; Kanduser M; Miklavcic D
Bioelectrochemistry; 2007 Nov; 71(2):113-7. PubMed ID: 17602896
[TBL] [Abstract][Full Text] [Related]
10. Blood levels of ruthenium following repeated treatments with the antimetastatic compound NAMI-A in healthy beagle dogs.
Sava G; Cocchietto M
In Vivo; 2000; 14(6):741-4. PubMed ID: 11204491
[TBL] [Abstract][Full Text] [Related]
11. Dual Action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen.
Sava G; Zorzet S; Turrin C; Vita F; Soranzo M; Zabucchi G; Cocchietto M; Bergamo A; DiGiovine S; Pezzoni G; Sartor L; Garbisa S
Clin Cancer Res; 2003 May; 9(5):1898-905. PubMed ID: 12738748
[TBL] [Abstract][Full Text] [Related]
12. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Rademaker-Lakhai JM; van den Bongard D; Pluim D; Beijnen JH; Schellens JH
Clin Cancer Res; 2004 Jun; 10(11):3717-27. PubMed ID: 15173078
[TBL] [Abstract][Full Text] [Related]
13. Reduction of lung metastasis by ImH[trans-RuCl4(DMSO)Im]: mechanism of the selective action investigated on mouse tumors.
Sava G; Clerici K; Capozzi I; Cocchietto M; Gagliardi R; Alessio E; Mestroni G; Perbellini A
Anticancer Drugs; 1999 Jan; 10(1):129-38. PubMed ID: 10194556
[TBL] [Abstract][Full Text] [Related]
14. Lack of In vitro cytotoxicity, associated to increased G(2)-M cell fraction and inhibition of matrigel invasion, may predict In vivo-selective antimetastasis activity of ruthenium complexes.
Zorzet S; Bergamo A; Cocchietto M; Sorc A; Gava B; Alessio E; Iengo E; Sava G
J Pharmacol Exp Ther; 2000 Dec; 295(3):927-33. PubMed ID: 11082425
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral NAMI-A treatment triggers metastasis reduction, which correlates to CD44 regulation and tumor infiltrating lymphocyte recruitment.
Pacor S; Zorzet S; Cocchietto M; Bacac M; Vadori M; Turrin C; Gava B; Castellarin A; Sava G
J Pharmacol Exp Ther; 2004 Aug; 310(2):737-44. PubMed ID: 15075381
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
[TBL] [Abstract][Full Text] [Related]
17. Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity.
Novohradský V; Bergamo A; Cocchietto M; Zajac J; Brabec V; Mestroni G; Sava G
Dalton Trans; 2015 Jan; 44(4):1905-13. PubMed ID: 25489765
[TBL] [Abstract][Full Text] [Related]
18. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity.
Bergamo A; Gava B; Alessio E; Mestroni G; Serli B; Cocchietto M; Zorzet S; Sava G
Int J Oncol; 2002 Dec; 21(6):1331-8. PubMed ID: 12429985
[TBL] [Abstract][Full Text] [Related]
19. Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine.
Sava G; Gagliardi R; Bergamo A; Alessio E; Mestroni G
Anticancer Res; 1999; 19(2A):969-72. PubMed ID: 10368640
[TBL] [Abstract][Full Text] [Related]
20. Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.
Bergamo A; Riedel T; Dyson PJ; Sava G
Invest New Drugs; 2015 Feb; 33(1):53-63. PubMed ID: 25338748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
